Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu, G., Searle, L.L., Hughes, T.V., Beck, A.K., Connolly, P.J., Abad, M.C., Neeper, M.P., Struble, G.T., Springer, B.A., Emanuel, S.L., Gruninger, R.H., Pandey, N., Adams, M., Moreno-Mazza, S., Fuentes-Pesquera, A.R., Middleton, S.A., Greenberger, L.M.(2008) Bioorg Med Chem Lett 18: 3495-3499
- PubMed: 18508264 
- DOI: https://doi.org/10.1016/j.bmcl.2008.05.024
- Primary Citation of Related Structures:  
3BEL - PubMed Abstract: 
We herein disclose a novel series of 4-aminopyrimidine-5-carbaldehyde oximes that are potent and selective inhibitors of both EGFR and ErbB-2 tyrosine kinases, with IC(50) values in the nanomolar range. Structure-activity relationship (SAR) studies elucidated a critical role for the 4-amino and C-6 arylamino moieties. The X-ray co-crystal structure of EGFR with 37 was determined and validated our design rationale.
Organizational Affiliation: 
Johnson & Johnson Pharmaceutical Research & Development, Medicinal Chemistry, 8 Clarke Drive, Cranbury, NJ 08512, USA. gxu4@prdus.jnj.com